# Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

> **NCT00551239** · PHASE3 · WITHDRAWN · sponsor: **CTI BioPharma**

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** fludarabine phosphate
- **DRUG:** pixantrone dimaleate

## Key facts

- **NCT ID:** NCT00551239
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551239, "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00551239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*